FibroBiologics Submits IND Application with the US FDA for CYPS317 in Patients with Psoriasis

Shots:

• The company has filed a P-I/II IND with the FDA to begin clinical trials of CYPS317 for mod. to sev. Psoriasis
• In animal studies, a single dose of CYPS317 matched or exceeded multiple anti-IL-23 mAb doses, showing durable effects and reduced disease recurrence
• CYPS317 is an investigational allogeneic fibroblast spheroid therapy for mod. to sev. Psoriasis pts.

Ref: FibroBiologics | Image: FibroBiologics |  Press Release

Related News: Cogent Biosciences Reports US FDA’s NDA Submission of Bezuclastinib for NonAdvanced Systemic Mastocytosis

PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com